Unlike testosterone therapy, estrogen therapy, growth hormone therapy, or other hormone-based treatments, BPC-157 is generally not considered a hormone replacement treatment
KLOW concentration at common reconstitution volumes BAC water 2.0 mL Total concentration 40.0 mg/mL GHK-Cu per unit (0.01 mL) ~250 mcg KPV / BPC-157 / TB-500 per unit ~50 mcg each BAC water 3.0 mL (most common) Total concentration 26.7 mg/mL GHK-Cu per unit (0.01 mL) ~167 mcg KPV / BPC-157 / TB-500 per unit ~33 mcg each BAC water 4.0 mL Total concentration 20.0 mg/mL GHK-Cu per unit (0.01 mL) ~125 mcg KPV / BPC-157 / TB-500 per unit ~25 mcg each Higher BAC water volumes give more measurable draws but require larger injection volumes
Anyone who aliquots the blend into smaller working amounts reduces repeated thawing of the entire batch
Enter BPC-157: a promising peptide offering a new and exciting route in the treatment and prevention of joint issues
TB-500, a synthetic analog of thymosin beta-4, has demonstrated benefits in modulating actin dynamics, improving cell migration, and promoting angiogenesis